Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In Vitro Susceptibility of Breakthrough Candida Bloodstream Isolates Correlates with Daily and Cumulative Doses of Fluconazole

27 Sept 2006

Abstract excerpt

We determined MICs for 28 Candida isolates recovered from patients who developed breakthrough candidemia while receiving fluconazole. MICs correlated with daily and cumulative doses of fluconazole. Patients receiving > or =2,000 mg cumulatively or >200 mg daily were more likely to be infected with isolates that were not fluconazole susceptible.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics Pharmacokinetics and Efficacy
Share to Antifungal resistance and susceptibility
Share to Antimicrobial Resistance in Staphylococcus

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17005842
DOI: 10.1128/aac.00741-06

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

In Vitro Susceptibility of Breakthrough Candida Bloodstream Isolates Correlates with Daily and Cumulative Doses of FluconazolePMID 17005842Read ↗

Breakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin.Semantic proximity Read ↗

Clonal and spontaneous origins of fluconazole resistance in Candida albicans.Semantic proximity Read ↗

Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year periodSemantic proximity Read ↗

Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida InfectionsSemantic proximity Read ↗

Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effect.Semantic proximity Read ↗

Correlation of MIC with Outcome for <i>Candida</i> Species Tested against Voriconazole: Analysis and Proposal for Interpretive BreakpointsSemantic proximity Read ↗

Variation in fluconazole efficacy for Candida albicans strains sequentially isolated from oral cavities of patients with AIDS in an experimental murine candidiasis model.Semantic proximity Read ↗

Breakthrough invasive fungal infections: Who is at risk?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.